HBV

Featured Resources

Podcasts

cardImg

The EASL Breakdown: Key Highlights from the European Liver Conference

11/04/2026

In this Chronic Liver Disease Foundation (CLDF) educational program, leading hepatology experts Dr. Ira Jacobson, Dr. Paul Kwo, and Dr. Tatyana Kushner explore the latest advances in hepatitis B (HBV) and hepatitis D (HDV) treatment, highlighting key clinical trial data presented at the European Association for the Study of the Liver (EASL) Congress 2026. The discussion examines emerging therapies aimed at achieving a functional cure for chronic hepatitis B, including pivotal Phase 3 B-Well trial results for bepirovirsen, the importance of quantitative hepatitis B surface antigen (HBsAg) testing in identifying eligible patients, and promising investigational approaches such as antisense oligonucleotides, epigenetic silencing, and gene-editing technologies targeting HBV DNA. The faculty also review advances in hepatitis D management, including clinical trial and real-world evidence for bulevirtide, emerging investigational therapies, treatment response rates, safety considerations, and the potential role of combination therapy. Throughout the program, the experts provide clinical perspectives on HBV and HDV screening, treatment selection, long-term viral suppression, and shared decision-making. Healthcare professionals, including hepatologists, gastroenterologists, and advanced practice providers (APPs), will gain valuable insights into evolving hepatitis B and hepatitis D treatment strategies, emerging clinical evidence, and the future of chronic viral hepatitis management.

Abstract Library

Unlocking Boundless Knowledge Through Abstracts

View All Modules arrow
alcbimg

Efficacy and safety of Tenofovir disoproxil fumarate (TDF) or Entecavir (ETV) combined with interferon for the treatment of chronic hepatitis B: a systematic review and meta-analysis.

07/27/2026

Yang Shuqi (S);Lin Yijie (Y);Yuan Wenjin (W);Liang Yanlan (Y);Zhang Huatang (H);Wang Xing (X);Li Jiaxuan (J);Lin Wenwu (W);Hong Wencong (W);Su Zhijun (Z);Yu Xueping (X)

alcbimg

Therapeutic advances in chronic hepatitis B and Delta: where are we now and where are we headed?

10/23/2026

Pocurull Anna (A);Battistella Sara (S);Forns Xavier (X);Lens Sabela (S)

alcbimg

Alpha-fetoprotein change after systemic treatments in advanced hepatocellular carcinoma: a systematic review and trial-level meta-analysis.

09/29/2026

Venturino Antonella (A);Colloca Giuseppe A (GA)